Eli Lilly has agreed to pay $125 million for an exclusive license to an experimental drug from Rigel Pharmaceuticals that the companies believe could be valuable in the treatment of autoimmune and inflammatory diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,